Ecolab delivered a record fourth quarter in 2025, with reported diluted EPS increasing by 19% to $1.98 and adjusted diluted EPS rising by 15% to $2.08. Net sales grew 5% to $4.2 billion, fueled by accelerating organic sales growth across most businesses and robust operating income margin expansion. The company also provided a strong outlook for 2026, anticipating continued growth in adjusted diluted EPS.

Ecolab delivered a strong third quarter driven by pricing acceleration, volume growth, and expanded operating margins. Life Sciences, Pest Elimination, and Institutional & Specialty led the growth, while softness persisted in Basic Industries and Paper.

Ecolab delivered another strong quarter, driven by pricing, volume growth, and productivity. Key segments including Life Sciences and Ecolab Digital contributed to margin expansion and earnings strength.

Ecolab achieved strong EPS growth in Q1 2025, driven by value pricing, productivity improvements, and resilient segment performances, while overcoming headwinds from softer market demand and currency impacts.

Ecolab delivered strong Q4 2024 performance with a 2% increase in revenue to $4.0 billion. Adjusted diluted EPS grew 17% to $1.81. Organic operating income margin improved by 150 bps to 17.4%. Segment performance was robust, with growth in Industrial and Institutional & Specialty segments offsetting a decline in Healthcare & Life Sciences. The company generated record free cash flow of $1.8 billion for the year.

Ecolab reported a 1% increase in sales to $4.0 billion, including a 2% headwind from the sale of the global surgical solutions business and a 1% headwind from currency exchange. Organic sales grew by 4%, driven by volume growth and value pricing. Adjusted diluted EPS increased by 19% to $1.83, and the company increased its full-year adjusted diluted EPS outlook to $6.60 - $6.70.

Ecolab reported a 3% increase in sales to $4.0 billion, with organic sales up 4%. The company's adjusted EPS grew by 35% to $1.68, driven by strong operating income margin expansion. Ecolab also raised its full-year adjusted EPS outlook to $6.50 - $6.70.

Ecolab reported strong first quarter results, with sales of $3.8 billion and adjusted diluted EPS of $1.34, a 52% increase year-over-year. The company raised its full-year adjusted diluted EPS outlook to $6.40 - $6.70.

Ecolab's fourth-quarter results demonstrated robust sales growth and significant operating margin expansion. The company's adjusted diluted earnings per share increased by 22%, driven by strong pricing, volume growth, and lower delivered product costs.

Ecolab reported an 8% increase in sales, reaching $4.0 billion, with organic sales up by 7%. The company's operating income rose by 17%, and adjusted diluted EPS increased by 18% to $1.54. Ecolab anticipates continued strength in the fourth quarter of 2023 and into 2024.

Ecolab delivered a strong second quarter, driven by robust organic sales growth and operating margin expansion. The company's adjusted diluted EPS grew by 13%, reflecting strategic decisions and strong execution. Management anticipates continued strong performance in the second half of 2023, driven by pricing, new business gains, and improved productivity.

Ecolab reported a strong first quarter with organic sales growth of 13% and adjusted EPS of $0.88, a 7% increase year-over-year. The company's performance was driven by double-digit growth in key segments and improved operating income margin.

Ecolab reported a 9% increase in sales to $3.7 billion in the fourth quarter of 2022. Reported diluted EPS was $0.93, while adjusted diluted EPS was $1.27. The company expects further performance improvement through 2023, anticipating double-digit growth in adjusted operating income.

Ecolab reported strong sales growth in the third quarter, driven by pricing actions and new business wins, but earnings were negatively impacted by currency translation and increased interest expenses. The company is implementing cost savings measures in Europe to mitigate the effects of the war in Ukraine and the energy crisis.

Ecolab reported a 13% increase in sales to $3.6 billion, with fixed currency sales up 17%. Adjusted diluted EPS was $1.10, a 10% decrease year-over-year, impacted by currency translation and Purolite amortization. The company expects improved performance in the second half of 2022.

Ecolab's first quarter earnings were consistent with expectations, with sales growth driven by volume gains and pricing that overcame surging delivered product cost inflation. Sales growth accelerated from the fourth quarter, led by double-digit gains in Institutional & Specialty, Industrial and Other segments. Raw material and freight costs increased an estimated 25% versus last year, exacerbated by the start of the war in Eastern Europe.

Ecolab reported a 10% increase in sales from continuing operations and an adjusted EPS of $1.28, a 4% increase versus last year, driven by pricing and volume growth, and lower pension and interest expense, offset by higher delivered product costs.

Ecolab reported strong third-quarter results, with sales from continuing operations up 10% versus last year and adjusted diluted EPS from continuing operations up 20%. The company leveraged market reopenings with new business wins, new products, and accelerated pricing to deliver strong sales and double-digit earnings growth.

Ecolab reported strong second-quarter results, leveraging recovering markets with new business wins and new products to deliver double-digit sales and earnings growth. Reported sales from continuing operations increased by 18% versus last year, and adjusted diluted EPS from continuing operations were $1.22, an increase of 88% versus last year.

Ecolab's first quarter earnings were affected by the Texas freeze, which had an estimated unfavorable impact of $0.10 per share. Reported sales decreased by 4%, while adjusted diluted EPS from continuing operations was $0.81, a decrease of 18% compared to the previous year.

Ecolab's fourth quarter earnings showed sequential improvement from the third quarter despite the negative impact from the greater than expected COVID-19 second wave. Reported sales from continuing operations decreased by 6% from the year-ago period. Adjusted diluted EPS from continuing operations were $1.23, a decrease of 15% versus last year.

Ecolab's third quarter results showed significant improvement from the second quarter, while still reflecting the divergent impacts of COVID-19 on the business segments. Strong top and bottom line growth in the Healthcare & Life Sciences segment and further strong income growth in the Industrial segment were more than offset by significant declines in the Institutional & Specialty and Other segments.

Ecolab's second quarter results were impacted by COVID-19, with a 15% decrease in reported sales. Adjusted EPS from continuing operations was $0.65, a 49% decrease. The Healthcare and Life Sciences segment showed strong growth, while the Institutional segment was heavily impacted by COVID-19 shutdowns.

Ecolab's first quarter reported diluted EPS was $0.97, a decrease of 4%, while adjusted diluted EPS was $1.13, a 10% increase. Reported sales increased by 2%. The company is not providing earnings forecasts due to the fluid nature of COVID-19 impacts.

Ecolab reported a 2% increase in sales and an 8% increase in adjusted diluted earnings per share for Q4 2019. The company's performance was driven by pricing, lower product costs, and cost efficiency actions, which offset investments and a Healthcare product recall. The company expects another strong earnings year in 2020, despite a challenging environment.